Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobomarsen vs Vorinostat in Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
NCT03713320Phase 2Terminated
- Sponsor
- Viridian Therapeutics
- Start
- Apr 2019
- Primary completion
- Oct 2020
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of cobomarsen in mycosis fungoides (MF) (2 arms), sponsored by Viridian Therapeutics. Primary endpoint: Objective Skin Response of at Least 4 Months Duration. Started Apr 2019; status: terminated.
02
Drugs
cobomarsen
03
Conditions
mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT03713320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03713320.